Kanti Thirumoorthy

Kanti Thirumoorthy currently serves as the CTO for T-cell therapy at AstraZeneca, responsible for CMC aspects related to T-cell therapies since October 2023. Prior to this role, Kanti Thirumoorthy held various leadership positions at Neogene Therapeutics, including SVP and VP of Technical Operations, where responsibilities encompassed building comprehensive Technical Operations and ensuring successful regulatory filings. Kanti Thirumoorthy's experience at Kite Pharma includes serving as Executive Director, leading B Cell Operations, and overseeing quality control and compliance functions. Additional roles include Principal Consultant at Quality Systems Solutions and Director of Quality Assurance at Obagi Medical Products. Kanti Thirumoorthy began the career as a Senior Scientist at PPD focused on analytical method development and validation and holds a Ph.D. in Chemistry from the Indian Institute of Technology, Madras.